Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA

Gastroenterology

Volumn 146, Issue 5, 2014, Pages 1240-1248

  Chan, Henry L Y ^a   Chan, Chi Kuen ^b   Hui, Aric Josun ^c   Chan, Sing ^d   Poordad, Fred ^e   Chang, Ting Tsung ^f   Mathurin, Philippe ^g   Flaherty, John F ^h   Lin, Lanjia ^h   Corsa, Amy ^h   Gaggar, Anuj ^h   Subramanian, G Mani ^h   McHutchison, John G ^h   Lee, Sam ⁱ   Gane, Edward J ^j  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^d Chan Sing Private Practice   (United States)

^e Texas Liver Institute   (United States)

^f NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h GILEAD SCIENCES   (United States)

ⁱ UNIVERSITY OF CALGARY   (Canada)

^j UNIVERSITY OF AUCKLAND   (New Zealand)

more..

Author keywords

Combination Therapy; FTC; HBsAg; Immune Tolerant; Keywords

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CREATININE; EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; PHOSPHATE; PLACEBO; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEPATITIS B; HEPATITIS B VIRUS; HOMICIDE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SPONTANEOUS ABORTION; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS RESISTANCE;

COMBINATION THERAPY; FTC; HBSAG; IMMUNE TOLERANT;

ADENINE; ADOLESCENT; ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DEOXYCYTIDINE; DNA, VIRAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHOSPHOROUS ACIDS; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84899449014     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.01.044     Document Type: Article

References (25)

1. J.L. Dienstag Hepatitis B virus infection N Engl J Med 359 2008 1486 1500
2. Y.-F. Liaw, and C.-M. Chu Hepatitis B virus infection Lancet 373 2009 582 592
3. T.T. Tran Immune tolerant hepatitis B: a clinical dilemma Gastroenterol Hepatol (N Y) 7 2011 511 516
4. C.-K. Hui, N. Leung, and S.-T. Yuen et al. Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase Hepatology 46 2007 395 401
5. T. Andreani, L. Serfaty, and D. Mohand et al. Chronic hepatitis B virus carriers in the immunotolerant phase of infection: histologic findings and outcome Clin Gastroenterol Hepatol 5 2007 636 641
6. M.H. Chang Natural history and clinical management of chronic hepatitis B virus infection in children Hepatol Int 2 2008 28 36
7. EASL clinical practice guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
8. A.S.F. Lok, and B.J. McMahon Chronic hepatitis B: update 2009 Hepatology 50 2009 661 662
9. Y.F. Liaw, J.H. Kao, and T. Piratvisuth et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update Hepatol Int 6 2012 531 561
10. M. Kumar, S.K. Sarin, and S. Hissar et al. Virologic and histologic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT Gastroenterology 134 2008 1376 1384
11. G.L.-H. Wong, V.W.-S. Wong, and P.C.-L. Choi et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients Clin Gastroenterol Hepatol 7 2009 227 233
12. W.-K. Seto, C.-L. Lai, and P.P.C. Ip et al. A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B PloS One 7 2012 e32622
13. P. Marcellin, E.J. Heathcote, and M. Buti et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N Engl J Med 359 2008 2442 2455
14. E.J. Heathcote, P. Marcellin, and M. Buti et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B Gastroenterology 140 2011 132 143
15. T.-T. Chang, R.G. Gish, and R. de Man et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B N Engl J Med 354 2006 1001 1010
16. G.L.-H. Wong, V.W.-S. Wong, and H.-Y. Chan et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years Aliment Pharmacol Ther 35 2012 1326 1335
17. G.L. Wong, V.W. Wong, and H.Y. Chan et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis Hepatology 58 2013 1537 1547
18. R. Zoutendijk, J.G.P. Reijnders, and F. Zoulim et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis Gut 62 2013 760 765
19. C.J. Chen, H.I. Yang, and J. Su et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level JAMA 295 2006 65 73
20. T. Berg, P. Marcellin, and F. Zoulim et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection Gastroenterology 139 2010 1207 1217
21. M.G. Peters, H.W. Hann, and P. Martin et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B Gastroenterology 126 2004 91 101
22. A.S. Lok, H. Trinh, and G. Carosi et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B Gastroenterology 143 2012 619 628
23. A. Snow-Lampart, B. Chappell, and M. Curtis et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus Hepatology 53 2011 763 773
24. S. Menne, S.D. Butler, and A.L. George et al. Antiviral effects of lamivudine, emtricitabine, adefovir dipivoxil, and tenofovir disoproxil fumarate administered orally alone and in combination to woodchucks with chronic woodchuck hepatitis virus infection Antimicrob Agents Chemother 52 2008 3617 3632
25. R. Zoutendijk, B.E. Hansen, and A.J. van Vuuren et al. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss J Infect Dis 204 2011 415 418